Literature DB >> 25103330

Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations.

Stephen E Langabeer1, Karl Haslam, Jennifer Linders, Melanie J Percy, Eibhlin Conneally, Amjad Hayat, Brian Hennessy, Maeve Leahy, Karen Murphy, Margaret Murray, Fionnuala Ni Ainle, Patrick Thornton, Jeremy Sargent.   

Abstract

The myeloproliferative neoplasms (MPN) are clonal, hematological malignancies that include polycythemia vera, essential thrombocythemia and primary myelofibrosis. While most cases of MPN are sporadic in nature, a familial pattern of inheritance is well recognised. The phenotype and status of the commonly acquired JAK2 V617F, CALR exon 9 and MPL W515L/K mutations in affected individuals from a consecutive series of ten familial MPN (FMPN) kindred are described. Affected individuals display the classical MPN phenotypes together with one kindred identified suggestive of hereditary thrombocytosis. In affected patients the JAK2 V617F mutation is the most commonly acquired followed by CALR exon nine mutations with no MPL W515L/K mutations detected. The JAK2 V617F and CALR exon 9 mutations appear to occur at approximately the same frequency in FMPN as in the sporadic forms of these diseases. The familial nature of MPN may often be overlooked and accordingly more common than previously considered. Characterisation of these FMPN kindred may allow for the investigation of molecular events that contribute to this inheritance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25103330     DOI: 10.1007/s10689-014-9743-2

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  34 in total

Review 1.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

2.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

3.  Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.

Authors:  Jerald Z Gong; James R Cook; Timothy C Greiner; Cyrus Hedvat; Charles E Hill; Megan S Lim; Janina A Longtine; Daniel Sabath; Y Lynn Wang
Journal:  J Mol Diagn       Date:  2013-08-24       Impact factor: 5.568

4.  Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.

Authors:  Sandra Malak; Myriam Labopin; Cecile Saint-Martin; Christine Bellanne-Chantelot; Albert Najman
Journal:  Blood Cells Mol Dis       Date:  2012-07-19       Impact factor: 3.039

5.  Looking for CALR mutations in familial myeloproliferative neoplasms.

Authors:  M Maffioli; A Genoni; D Caramazza; B Mora; A Bussini; M Merli; T Giorgino; R Casalone; F Passamonti
Journal:  Leukemia       Date:  2014-01-20       Impact factor: 11.528

6.  A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis.

Authors:  S Leah Etheridge; Megan E Cosgrove; Veena Sangkhae; Lana M Corbo; Michelle E Roh; Markus A Seeliger; Edward L Chan; Ian S Hitchcock
Journal:  Blood       Date:  2013-12-31       Impact factor: 22.113

7.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

Review 8.  Inheritance of the chronic myeloproliferative neoplasms. A systematic review.

Authors:  A Ranjan; E Penninga; A M Jelsig; H C Hasselbalch; O W Bjerrum
Journal:  Clin Genet       Date:  2012-11-20       Impact factor: 4.438

Review 9.  Therapy with JAK2 inhibitors for myeloproliferative neoplasms.

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Hematol Oncol Clin North Am       Date:  2012-08-21       Impact factor: 3.722

Review 10.  Familial chronic myeloproliferative disorders: the state of the art.

Authors:  Elisa Rumi
Journal:  Hematol Oncol       Date:  2008-09       Impact factor: 5.271

View more
  3 in total

1.  Lentiginoses in polycythemia vera patient: Is there a role for JAK2 (V617F) mutation?

Authors:  Tugba Kevser Uzuncakmak; Sarenur Yilmaz; Ayse Serap Karadag; Necmettin Akdeniz; Ibrahim Akalin
Journal:  JAKSTAT       Date:  2015-07-24

2.  Familial Essential Thrombocythemia Associated with MPL W515L Mutation in Father and JAK2 V617F Mutation in Daughter.

Authors:  Adrian P Trifa; Andrei Cucuianu; Radu A Popp
Journal:  Case Rep Hematol       Date:  2014-11-10

Review 3.  JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms.

Authors:  Dania G Torres; Jhemerson Paes; Allyson G da Costa; Adriana Malheiro; George V Silva; Lucivana P de Souza Mourão; Andréa M Tarragô
Journal:  Biomolecules       Date:  2022-02-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.